Phase II clinical pharmacology study of KRP-AB1102F DPI

A Phase II, Repeated-dose clinical pharmacology Study, Evaluating the Pharmacokinetics and Safety of KRP-AB1102F DPI in Patients With Mild to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222176

Enrollment

Registered

2013-08-20

Start date

2013-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

investigational material(s) Generic name etc : KRP-AB1102F DPI INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administration fo

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: COPD patients with post-bronchodilator FEV1 between 30 % and more of predicted

Exclusion criteria

Exclusion criteria: - Patient hospitalized for an acute COPD exacerbation within 3 months prior to hospitalization day for this study - Current active tuberculopsis, and others

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics Plasma concentration of KRP-AB1102	—

Secondary

Measure	Time frame
Advers events, and others Clinical laboratory test, and others	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026